Biomarin Pharmaceutical Stock Target Price and Analyst Consensus
| BMRN Stock | USD 89.49 0.86 0.97% |
The current analyst and expert consensus on Biomarin Pharmaceutical is Strong Buy with 7 buy recommendations. The current projected Biomarin Pharmaceutical target price consensus is 116.95, with 30 analyst opinions. The most common way Biomarin Pharmaceutical analysts use to provide public buy-or-sell recommendation is financial statements analysis. They also talk to Biomarin Pharmaceutical executives, vendors, and/or customers. Biomarin Pharmaceutical buy-or-sell recommendation module provides average expert sentiment on the projected Biomarin Pharmaceutical target price to derive its highest and lowest estimates based on target price estimated volatility of 0.0. Check out Macroaxis Advice on Biomarin Pharmaceutical to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.
Lowest Forecast 106.42 | Highest Forecast 129.81 | Target Price 116.95 |
Biomarin |
It's important to approach Biomarin Pharmaceutical's target price projections with caution. While they can be useful as part of a broader investment strategy, they are inherently speculative and subject to various kinds of risk, including market volatility and unforeseen external factors. Always consider multiple aspects and do your own research when making investment decisions.
Analysts determine stock price targets through various methods, including financial modeling, peer comparison, and company analysis. The stock price target is the analyst's best estimate of the future price of a stock and is used by investors to make investment decisions. However, it is important to note that stock price targets are not guaranteed, and the actual price of a stock can differ significantly from the target due to various factors such as market conditions, economic events, and company developments.
Steps to utilize Biomarin Pharmaceutical price targets
Biomarin Pharmaceutical's stock target price is an estimate of its future price, usually made by analysts. Using Biomarin Pharmaceutical's target price to determine if it is a suitable investment can be done through the following steps:- Look at Biomarin Pharmaceutical's target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential.
- Look at the analyst's track record to determine if they have a history of accurately predicting stock prices.
- Look at the Company's financials, including revenue, earnings, and debt, to determine if it is in good financial health.
- Consider market conditions. For example, take into account the state of the economy, competition, and regulatory environment, to determine if Biomarin Pharmaceutical's stock is likely to perform well.
- Diversify your portfolio and do not rely solely on stock target prices to make investment decisions. Invest in a mix of stocks, bonds, and other assets to manage risk.
Additional Biomarin Pharmaceutical Value Projection Modules
Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Biomarin Pharmaceutical is a key component of Biomarin Pharmaceutical valuation and have some predictive power on the future returns of a Biomarin Pharmaceutical.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Biomarin Pharmaceutical's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Social Domain Invested a lot of shares | |
 | Chemicals Invested over 40 shares | |
 | Momentum Invested over 50 shares | |
 | Artificial Intelligence Invested few shares | |
 | Automobiles and Trucks Invested over 70 shares | |
 | Driverless Cars Invested over 200 shares | |
Check out Macroaxis Advice on Biomarin Pharmaceutical to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Biomarin Stock analysis
When running Biomarin Pharmaceutical's price analysis, check to measure Biomarin Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biomarin Pharmaceutical is operating at the current time. Most of Biomarin Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Biomarin Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biomarin Pharmaceutical's price. Additionally, you may evaluate how the addition of Biomarin Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |
The data published in Biomarin Pharmaceutical's official financial statements usually reflect Biomarin Pharmaceutical's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Biomarin Pharmaceutical. For example, before you start analyzing numbers published by Biomarin accountants, it's critical to develop an understanding of what Biomarin Pharmaceutical's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Biomarin Pharmaceutical's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Biomarin Pharmaceutical's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Biomarin Pharmaceutical's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Biomarin Pharmaceutical. Please utilize our Beneish M Score to check the likelihood of Biomarin Pharmaceutical's management manipulating its earnings.